Friday broker round-up
15th Nov 2019 13:09
(Sharecast News) - Whitbread: Barclays upgrades to overweight with a target price of 4,900p.
Read moreShoreCap stays at 'buy' on AstraZeneca after EU approves Qtrilmet
15th Nov 2019 11:25
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation on shares of AstraZeneca following news that Brussels had approved its Qtrilmet treatment for controlling blood sugar levels in patients suffering from Type-2 diabetes.
Read moreAstraZeneca gets EC approval for type-2 diabetes treatment
15th Nov 2019 07:28
(Sharecast News) - AstraZeneca announced on Friday that the European Commission has approved 'Qtrilmet' - metformin hydrochloride, saxagliptin and dapagliflozin - modified-release tablets to improve glycaemic control in adults with type-2 diabetes.
Read moreFDA accepts new drug application for AstraZeneca's selumetinib
14th Nov 2019 07:37
(Sharecast News) - AstraZeneca, along with its partner MSD, announced on Thursday that the US Food and Drug Administration (FDA) has accepted a new drug application (NDA) and granted 'Priority Review' status for selumetinib, as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas.
Read moreTuesday broker round-up
12th Nov 2019 13:31
(Sharecast News) - BBA Aviation: HSBC downgrades to hold with a target price of 330p.
Read moreAstraZeneca's anifrolumab succeeds in lupus study
12th Nov 2019 08:05
(Sharecast News) - Biopharmaceutical giant AstraZeneca's anifrolumab demonstrated superiority across multiple efficacy endpoints versus placebos in the drug's Phase III TULIP 2 trial.
Read moreAstraZeneca upbeat on latest roxadustat trial data
11th Nov 2019 07:55
(Sharecast News) - AstraZeneca, along with its partner FibroGen, presented pooled efficacy and cardiovascular safety analyses from the pivotal phase 3 programme assessing 'roxadustat' on Monday, for the treatment of patients with anaemia from chronic kidney disease (CKD).
Read moreAstraZeneca reports positive trials for kidney drug
8th Nov 2019 07:50
(Sharecast News) - AstraZeneca on Friday reported clinical trials of its roxadustat drug for patients with anaemia from chronic kidney disease had significantly increased red haemoglobin levels.
Read moreThursday broker round-up
7th Nov 2019 13:28
(Sharecast News) - Associated British Foods: Goldman Sachs upgrades to buy with a target price of 2,750p.
Read moreAstraZeneca offloads Europe and Russia rights to 'Seroquel' medicines
30th Oct 2019 07:31
(Sharecast News) - AstraZeneca has agreed the sale and licence of the commercial rights to 'Seroquel' - quetiapine fumarate immediate release - and 'Seroquel XR' - quetiapine fumarate extended release - in Europe and Russia to Cheplapharm Arzneimittel, it announced on Wednesday.
Read moreLiberum upgrades AstraZeneca to 'buy' despite near-term premium
25th Oct 2019 13:23
(Sharecast News) - Analysts at Liberum upgraded their recommendation for shares of AstraZeneca, arguing that the consensus was - yet again - underestimating just how leveraged the firm was to its product pipeline.
Read moreFriday broker round-up
25th Oct 2019 12:56
(Sharecast News) - AstraZeneca: Liberum upgrades to buy with a target price of 8,250p.
Read moreAstraZeneca upgrades sales guidance after third quarter growth
24th Oct 2019 07:51
(Sharecast News) - AstraZeneca reported its year-to-date results following the end of its third quarter on Thursday, claiming that patients would benefit from further progress to its pipeline, while sales-growth momentum continued to drive its operating leverage.
Read moreFDA approves AstraZeneca drug for heart failure risk
21st Oct 2019 07:16
(Sharecast News) - AstraZeneca on Monday announced that its Farxiga treatment against heart failure risk in certain patient groups has received approval from the US Food and Drug Administration.
Read moreAstraZeneca breast cancer drug candidate clears FDA hurdle
17th Oct 2019 07:37
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo Company, announced on Thursday that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for trastuzumab deruxtecan, or DS-8201, and granted it 'Priority Review' status.
Read more